Obesity affects approximately 100 million Indian adults and is linked to over 200 health complications, including heart ...

The future of medicine is being shaped by a confluence of factors at play. If there are worries galore around drug resistant ...

The drug will be priced at ₹3,500 for a 2.5 mg vial and ₹4,375 for the 5 mg vial. The injectable, to be taken once a week, ...

US pharma giants eye India’s obesity crisis with pricey shots, sparking ‘Make in India’ and affordability debates ...

Eli Lilly on Thursday launched in India its diabetes and weight-loss drug, Mounjaro, which has already clocked in over $20 ...

New Delhi: Cancer patients facing prohibitive treatment costs in India can hope for relief: the nation's top drugmakers have started manufacturing key medicines for such diseases in the country.

Here are the local and international drugmakers also eyeing the Indian market and looking to introduce rivals to Lilly's drug ...

Corner office conversation: Cipla CEO on innovation, obesity drugs, AI and more Posted: 3 March 2025 | Last updated: 3 March 2025 The life of Cipla, the Indian pharma giant, can broadly be divided ...

US giant, Eli Lilly launched Mounjaro (tirzepatide) which is a prescription medicine for adults with type 2 diabetes used ...

Cipla Limited is an Indian multinational pharmaceutical company that is headquartered in Mumbai, Maharashtra. The company is primarily known for producing generic drugs for various therapeutic uses.

India's obesity crisis is intensifying, with big pharma companies like Eli Lilly and Novo Nordisk competing to introduce ...